Abstract
Urogenital prolapse is a common, distressing condition. Although significant morbidity and certainly mortality related to this condition is extremely rare, it has a significant impact on quality of life (QoL). QoL has been used as a surrogate measure of patient satisfaction and success following treatment of prolapse. Although highly subjective, QoL has been acknowledged to be as important as physical disease state and there are now several validated questionnaires to assess both symptoms and their impact on patients’ lives. As these questionnaires are relatively long and therefore difficult to use in clinical settings, alternatives such as patient-centered goal achievement and global indices (Patient Global Impression of Improvement), which are simple and easy to use, have gained popularity. Incorporation of QoL as an outcome measure may help to tailor patient care and ultimately improve patient satisfaction following treatment of urogenital prolapse.
Financial & competing interests disclosure
Sushma Srikrishna received speaker honoraria from Recordati, Astellas and SEP; and is on the advisory board for Astellas. Dudley Robinson consults for Astellas, Ferring, Gynaecare, Uroplasty, Pfizer, Recordati and Novo-Nordisk; has received speaker honoraria from Astellas, Ferring, Gynaecare, Uroplasty, Pfizer and Recordati; and has participated in trials for Astellas and Pfizer. Linda Cardozo consults for Astellas, Pfizer, Rottapharm and SEP; has received speaker honoraria from Astellas, Pfizer and Rottapharm; has participated in trials for Astellas and Pfizer; and received a research grant from Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.